Find stats on top websites
Major Markets
Key Competitors
Biocogniv is positioned as a leader in AI-powered diagnostics for acute care, specializing in early detection of critical conditions like sepsis using routine lab tests to reduce preventable hospital deaths and improve patient outcomes.
Customer sentiment appears highly positive, as evidenced by testimonials from key healthcare leaders validating Biocogniv's value proposition for large healthcare organizations and their integration capabilities. The successful collaboration with UTMB and FDA Breakthrough Designation further solidify trust and confidence in their technology.
Biocogniv's key value proposition is enabling earlier, more accurate recognition of acute medical conditions through AI-powered digital diagnostics like Sepsis aiMarker™, which utilizes routine lab tests to predict conditions up to 72 hours in advance. This capability directly leads to reduced preventable hospital deaths, morbidities, and healthcare costs by allowing for timely intervention and improved patient outcomes.
FDA Breakthrough Designation for Sepsis aiMarker™.
Leverages routine lab tests, easy integration.
Strong leadership and advisory board.
No specified pricing model available publicly.
Dependency on hospital IT integration processes.
Niche focus on acute care might limit broader reach.
Expand into other acute conditions beyond sepsis.
Partnerships with more healthcare systems.
Develop further AI models with vast data.
Regulatory changes in AI/medical devices.
Competition from other diagnostic companies.
Resistance to AI adoption in healthcare.
Biocogniv's primary market is the US, with limited but emerging presence in Canada, UK, Germany, and Australia, reflecting its initial focus on established healthcare systems.
United States
90% market share
Canada
3% market share
United Kingdom
2% market share
Germany
2% market share
Australia
2% market share
40-65 years
Male • Female
United States • Canada • Western Europe
35-60 years
Male • Female
United States • Canada • Western Europe
35-60 years
Male • Female
United States • Global Large Hospitals
30-55 years
Male • Female
United States • Major Metropolitan Areas
45-65 years
Male • Female
United States • Global Healthcare Hubs
Data shown in percentage (%) of usage across platforms
Develop an interactive ROI calculator on Biocogniv's website to allow potential hospital clients to estimate the cost savings and improved patient outcomes achievable with Sepsis aiMarker™. This will help hospital administrators visualize the tangible value and justify the investment in Biocogniv's AI diagnostics.
Learn moreOffer a product satisfaction guarantee to hospitals implementing Sepsis aiMarker™. This reduces the perceived risk associated with adopting a new technology and builds confidence in the effectiveness and reliability of Biocogniv's diagnostic platform.
Learn moreShowcase testimonials from hospitals and healthcare leaders (like Dr. Tamayo-Sarver and Dr. McCaffrey) on the website, landing pages, and marketing materials. This provides powerful social proof and demonstrates the real-world impact of Biocogniv's AI solutions in improving patient care and reducing hospital deaths.
Learn moreSign up now and unleash the power of AI for your business growth